Losses
-€4.1m in five years
Every financial year from 2021 to 2025 closed with a loss. 2025 was the heaviest.
SIMABS
Overview
Lifetime
6 annual accounts with figures on one time axispeak €371,722 (2020)
-€129,335▼ €24,146
lowest -€1.5m (2025)
-€1.5m▼ €487,832
peak €1.0m (2021)
€1.0m▲ €1.3m
€1.7m▲ 15.0%
peak 11.4 FTE (2025)
11.4 FTE▲ 56.2%
Board11 names since 2019
9 directorsEYE-TEC and 8 others
Owners4 names in the annual accounts
37.08%QbD Growth and 2 others
Documentsfilings and deeds
30-07-20261 day before the deadline
2025financial year
Gross margin from -€105,189 to -€129,335Loss of €1.5mStaff from 7.3 FTE to 11.4 FTE1 director appointed 05-09Equity from -€337,049 to €1.0mDebts from €1.4m to €1.7m
Key points
from the 2025 annual accountsInvestments
€392,865 1.9 × depreciation
Green is investment, beige is depreciation. Machinery stands 340.2% higher than in 2024.
Staff
12 employees on 31-12-2025
In 2025, 4 people joined and 3 left.
Filings
6 annual accounts since 2020
The last five annual accounts were filed 1 to 28 days before the end of the period.
Board
2 joined · 6 left
Board changed. Latest change 05-01-2026 · 4 in office.
Position in the sector
-€1.5m
Lower net result than 89% of companies in pharmaceuticals. Sector median €358,757 · 95 companies.
Checked score
56
Fair
Financially stronger than 57% of small companies in pharmaceuticals (NACE 21)
Probability in this band: 1.5% to 4.2%
A net loss of at least half of total assets or of the equity at the start of the financial year caps the score at 59.
Bankruptcy probability within 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 44 companies (NACE 21, small).
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025
08-2025: 3.0%▲ +2.8 percentage points vs 07-2025
09-2025: 3.0%● unchanged vs 08-2025
10-2025: 3.4%▲ +0.4 percentage points vs 09-2025
11-2025: 4.3%▲ +0.9 percentage points vs 10-2025highest value
12-2025: 4.3%● unchanged vs 11-2025highest value
01-2026: 4.2%▼ -0.1 percentage points vs 12-2025
02-2026: 4.2%● unchanged vs 01-2026
03-2026: 4.1%▼ -0.1 percentage points vs 02-2026
04-2026: 4.1%● unchanged vs 03-2026
05-2026: 4.1%● unchanged vs 04-2026
06-2026: 3.9%▼ -0.2 percentage points vs 05-2026
07-2026: 4.1%▲ +0.2 percentage points vs 06-2026
08-2026: 0.6%▼ -3.5 percentage points vs 07-2026
09-2026: 0.6%● unchanged vs 08-2026
10-2026: 0.6%● unchanged vs 09-2026
11-2026: 0.6%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Capped at 59: a net loss of at least half of total assets or of the equity at the start of the financial year
Loss of €1.5m, the second in a row (financial year 2025)
lowers risk
Liquidity: current ratio 1.50, cash €970,589
Figures for financial year 2025 (filed on 01-08-2026)
Sector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, small). It does better than 30% of them on solvency, 86% on liquidity, 14% on profitability and 98% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 224 companies had the same profile as SIMABS has now. Each dot is one company, two years later.
88.4%
were still trading
7.1%
stopped another way
4.0%
went bankrupt
Another 0.4% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of SIMABS itself is lower: 0.6% within 12 months. It rests on far more data about SIMABS than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 224 companies, not a prediction for SIMABS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €55,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity is ample, with a current ratio of 1.5 (1.67 in 2024), above the usual 1.5. Short-term debt is 51.4% and cash 36.4% of total assets. However, 62.4% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
1 day early
2024
8 days early
2023
2 days early
2022
1 day early
2021
28 days early
2020
23 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 6 accounts on average 11 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 30 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
CM
Chemsciences Middle East Fzc
Director, Amit Tibrewala
- QbD Growth 37.08%equity €98.9m (2025) · 2025 annual accounts of QbD Growth
- Pilot Biologix 18.54%equity €398,715 (2025) · 2025 annual accounts of Pilot Biologix
- Oak Projects 2.91%score 96equity €414,397 (2025) · 2025 annual accounts of Oak Projects
Recent changes
Capital increase of €1,500,000 to €6,221,600
Capital from €4,721,600 to €6,221,600, 20,280,378 new shares · General meeting of 06-03-2026 · Gazette deed
Environmental permit granted
Bouwen of herbouwen, Verbouwen en/of uitbreiden zonder functiewijziging en zonder wijziging van aantal woongelegenheden · Provincie Limburg
5 directors appointed, 7 resignations
Capital from €1,906,600 to €3,241,600, 18,049,537 new shares · Capital from €4,271,600 to €5,771,600, 20,280,378 new shares · Contribution of €1,480,000 · General meeting of 16-12-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0732709096
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SIMABS Diepenbeek | - | - | 37.6% | 11.4 |
| Obulytix Ghent | - | - | 41.9% | 4.3 |
| Temmune Therapeutics Mechelen | - | - | 58.6% | - |
| PREVOR Liège | €3.9m | 11.4% | 36.1% | 19 |
| Groovy.Bio Evergem | - | - | 73.2% | 0.2 |
| CENTRALE AFDELING VOOR FRACTIONERING Brussels | €11.2m | -15.1% | 94.9% | 13.2 |
| ALEXION PHARMA BELGIUM Brussels | €20.8m | 3.2% | 39.7% | 9.3 |
These companies have the same main activity as SIMABS: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €744,000 and €20m, founded between 2008 and 2023.
Official details
Source: KBO- Status
- Active since 20-08-2019Normal situation
- Registered office
- 15 active companies are registered at this addressSource: KBO register, as of 10 November 2026.
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 3 others
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment units
- 2.292.355.8643590 Diepenbeek, since 20-08-2019
- 2.378.436.3373590 Diepenbeek, since 25-09-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 25-11-2025
Annual accounts 2025
- -€129,335▼ 23.0%
- €1.5m▲ 49.4%
- €1.0m
- €2.7m▲ 140%
- Employeeson 31-12-2025
- 12▲ 9.1%
- Filing
- Filed on 30-07-2026, 1 day before the end of the filing period
Insights on SIMABS
Solvency rose in 2025 from -30.3% to 37.6% because of a capital increase.
In January 2026, six directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
full format, filed on 30-07-2026, 1 day before the deadline-€129,335
▼ €24,146
-€1.4m
▼ €480,229
-€1.5m
▼ €487,832
€692,436
▲ 151%
37.6%
▲ 67.9 percentage points
1.50
▼ 0.17
Turnover: not included in this filing.
Balance sheet
balance sheet total €2.7m on 31-12-2025What the company ownsHow it is paid for
in €m
in €m
Position in the sector
37.6%
Higher than 39% of 95 companies in 2025.
1.50
Higher than 46% of 94 companies in 2025.
-55.3%
Higher than 6% of 95 companies in 2025.
SIMABS
Middle half of the sector
80% of the sector
Full accounts in pharmaceuticals (NACE 21)
Net result: bottom quarter · Equity: middle half · Balance sheet total: middle half · Working capital: middle half · Staff: middle half
Staff
€95,774
Staff costs divided by the average number of full-time equivalents.
+1 person
people who joined
people who left
In 2025, 4 people joined and 3 left.
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Balance sheet: assets | |||||||
20/58 |
2.7m | 1.1m | 1.4m | 1.2m | 2.2m | 1.4m | |
21/28 |
604,030 | 422,450 | 545,424 | 736,874 | 850,535 | 68,514 | |
21 |
3,653 | 7,218 | 10,784 | 14,349 | - | - | |
22/27 |
580,326 | 395,181 | 528,380 | 716,226 | 844,295 | 64,869 | |
23 |
425,265 | 96,615 | 77,631 | 102,766 | 570,401 | 63,814 | |
24 |
0 | 197 | 412 | 626 | 841 | 1,055 | |
25 |
146,708 | 287,842 | 450,338 | 612,833 | 273,054 | - | |
26 |
8,354 | 10,527 | - | - | - | - | |
28 |
20,051 | 20,051 | 6,260 | 6,300 | 6,240 | 3,645 | |
29/58 |
2.1m | 688,428 | 880,856 | 450,229 | 1.4m | 1.3m | |
29 |
320,000 | - | - | - | - | - | |
291 |
320,000 | - | - | - | - | - | |
3 |
69,754 | 69,754 | 58,274 | 58,834 | 48,459 | - | |
30/36 |
69,754 | 69,754 | 58,274 | 58,834 | 48,459 | - | |
40/41 |
682,535 | 455,908 | 149,855 | 47,154 | 43,099 | 17,423 | |
40 |
156,513 | 378,458 | 149,562 | 27,931 | 517 | 156 | |
41 |
526,022 | 77,450 | 293 | 19,222 | 42,583 | 17,268 | |
54/58 |
970,589 | 162,766 | 672,241 | 342,342 | 826,150 | 1.3m | |
490/1 |
21,866 | 0 | 486 | 1,900 | 464,328 | - | |
| Balance sheet: equity and liabilities | |||||||
10/49 |
2.7m | 1.1m | 1.4m | 1.2m | 2.2m | 1.4m | |
10/15 |
1.0m | -337,049 | 649,820 | 271,415 | 1.0m | 835,361 | |
10/11 |
4.7m | 1.9m | 1.9m | 1.1m | 1.1m | 500,000 | |
10 |
4.7m | 1.9m | 1.9m | 1.1m | 1.1m | - | |
100 |
4.7m | 1.9m | 1.9m | 1.1m | 1.1m | 500,000 | |
13 |
50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 335,361 | |
130/1 |
50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | |
130 |
50,000 | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | |
133 |
- | - | - | - | - | 285,361 | |
14 |
-3.8m | -2.3m | -1.3m | -853,585 | -85,486 | - | |
17/49 |
1.7m | 1.4m | 776,460 | 915,689 | 1.2m | 537,397 | |
17 |
261,730 | 777,162 | 354,533 | 601,333 | 498,727 | 389,019 | |
170/4 |
261,730 | 777,162 | 354,533 | 601,333 | 498,727 | 389,019 | |
42/48 |
1.4m | 412,265 | 421,927 | 314,357 | 694,330 | 148,379 | |
42 |
128,736 | 209,364 | 246,800 | 242,279 | 163,514 | 95,330 | |
44 |
1.1m | 129,211 | 106,467 | 28,641 | 507,406 | 46,081 | |
440/4 |
1.1m | 129,211 | 106,467 | 28,641 | 507,406 | 46,081 | |
45 |
104,043 | 73,690 | 68,660 | 43,437 | 23,409 | 6,858 | |
450/3 |
3,773 | 1,708 | 26,156 | 487 | 196 | 24 | |
454/9 |
100,270 | 71,982 | 42,504 | 42,950 | 23,213 | 6,834 | |
47/48 |
- | - | - | - | - | 109 | |
492/3 |
31,485 | 258,500 | - | - | - | - | |
| Income statement | |||||||
76A |
0 | 196 | - | 1,778 | - | - | |
9900 |
-129,335 | -105,189 | 121,285 | -236,868 | -120,385 | 371,722 | |
62 |
1.1m | 661,307 | 363,862 | 333,246 | 186,408 | 21,309 | |
630 |
211,286 | 195,945 | 191,411 | 172,149 | 50,900 | 1,104 | |
640/8 |
11,742 | 1,516 | 2,247 | 2,106 | 512 | 1,002 | |
9901 |
-1.4m | -963,957 | -436,235 | -744,370 | -358,205 | 348,307 | |
75/76B |
316 | 1,752 | 718 | 19 | 99 | - | |
75 |
316 | 1,752 | 718 | 19 | 99 | - | |
65/66B |
28,766 | 23,553 | 17,103 | 23,262 | 12,568 | 12,921 | |
65 |
28,766 | 23,553 | 17,103 | 23,262 | 12,568 | 12,921 | |
9903 |
-1.5m | -985,758 | -452,620 | -767,612 | -370,675 | 335,386 | |
67/77 |
2,065 | 1,111 | 574 | 487 | 172 | 24 | |
9904 |
-1.5m | -986,869 | -453,195 | -768,099 | -370,847 | 335,361 | |
9905 |
-1.5m | -986,869 | -453,195 | -768,099 | -370,847 | 335,361 | |
| Appropriation of the result | |||||||
9906 |
-3.8m | -2.3m | -1.3m | -853,585 | -370,847 | 335,361 | |
14P |
-2.3m | -1.3m | -853,585 | -85,486 | - | - | |
791/2 |
- | - | - | - | 285,361 | - | |
691/2 |
- | - | - | - | - | 335,361 | |
6920 |
- | - | - | - | - | 50,000 | |
6921 |
- | - | - | - | - | 285,361 | |
| Social balance sheet | |||||||
9087 |
11.4 | 7.3 | 4 | 4.4 | 3 | 1.3 | |
Hours worked1013 |
18,442 | 12,034 | 6,827 | 7,388 | 5,371 | 616 | |
| Document | |||||||
The notes to these accounts have 22 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 30-07-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 30-07-2026 | 2026-00368030 | |
| 31-12-2024 | abbreviated format | 23-07-2025 | 2025-00298330 | |
| 31-12-2023 | micro format | 29-07-2024 | 2024-00298787 | |
| 31-12-2022 | abbreviated format | 30-07-2023 | 2023-00296677 | |
| 31-12-2021 | abbreviated format | 03-07-2022 | 2022-20125120 | |
| 31-12-2020 | abbreviated format | 08-07-2021 | 2021-33300023 |
Subsidies and aid
Flemish government 2024 to 2025, 6 entries, €549,154 awarded, €440,917 paid
| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 5 | €14,917 | €227,917 |
| 2024 | 1 | €534,237 | €213,000 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| -1.2m | -768,012 | -244,824 | -572,220 | -307,305 | 349,411 | ||
| -1.3m | -790,924 | -261,784 | -595,950 | -319,947 | 336,465 | ||
| 392,865 | 216,340 | -40 | 540,698 | 833,221 | 69,618 | ||
| 807,823 | -509,475 | 329,899 | -483,808 | -460,671 | - | ||
| 692,436 | 276,163 | 458,929 | 135,873 | 687,707 | 1.2m | ||
| 37.6% | -30.3% | 45.6% | 22.9% | 46.6% | 60.9% | ||
| 1.50 | 1.67 | 2.09 | 1.43 | 1.99 | 8.79 | ||
| 1.45 | 1.50 | 1.95 | 1.25 | 1.92 | 8.79 | ||
| 1.66 | - | 1.19 | 3.37 | 1.15 | 0.64 | ||
| -147.0% | - | -69.7% | -283.0% | -35.7% | 40.1% | ||
| -55.3% | -88.8% | -31.8% | -64.7% | -16.6% | 24.4% | ||
| -42.86 | -32.61 | -14.31 | -24.60 | -24.45 | - |
EBIT margin: not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Social balance sheet
| Item | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 12 | 11 | 5 | 5 | 3 |
| full-time | 12 | 10 | 4 | 4 | 3 |
| part-time | 0 | 1 | 1 | 1 | - |
| in full-time equivalents | 12 | 10.8 | 4.8 | 4.8 | 3 |
| 11.4 | 7.3 | 4 | 4.4 | 2.9 | |
| On a permanent contract | 12 | 11 | 5 | 5 | 3 |
| Joined | 4 | 7 | 1 | 2 | 2 |
| Left | 3 | 1 | 1 | 0 | 1 |
| Training hours | - | 12 | - | - | - |
Source: social balance sheet in the 2021 to 2025 annual accounts
Securities and guarantees
on own assets and for others| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Debts secured on the company's own assets | - | - | - | €552,408 | €273,223 |
| Carrying value of the other pledged assets | €146,708 | €287,842 | €450,338 | €612,833 | €273,054 |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
fixed assets acquired| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tangible fixed assets | €392,865 | €202,549 | - | €522,802 | €830,326 |
| Intangible fixed assets | - | - | - | €17,826 | - |
| Financial fixed assets | €0 | €13,791 | - | €70 | €2,895 |
| €211,286 | €195,945 | €191,411 | €172,149 | €50,900 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Insights on SIMABS
The operating result for 2025 is a loss of €1.4m, larger than the loss of €963,957 in 2024. It is the lowest result since 2020.
Debt's share of the balance-sheet total is 62.4%.
Large changes and their cause
- 2024 Net result -118% on 2023. The accounts now follow the abbreviated format, last year the micro format.
- 2023 Equity +139% on 2022. Capital increase of €831,600 (Official Gazette 20-10-2023).
Board & ownership
Board
4 directors, no change since January 2026Chemsciences Middle East Fzc
Director, permanent representative Amit Tibrewala
current term since 16-12-2025
listed in the 2025 annual accounts, filed on 30-07-2026
QbD Growth BV
Director, permanent representative Bart Van Acker
since 16-12-2025
also on the board of 3 other companies
listed in the 2025 annual accounts, filed on 30-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “De vennootschap zal geldig worden vertegenwoordigd tegenover derden en in rechte wanneer ten minste twee (2) bestuurders gezamenlijk…”deed of 20-10-2023
Permanent representatives 2
Amit Tibrewala
Permanent representative, for Chemsciences Middle East Fzc
appointed by deed of 05-09-2025
Mandates through the years
11 names, the dashed line is todayChemsciences Middle East Fzc
Director
Director
QbD Growth
Director
Director
VANDECRUYS Amber
Director
Director
Chemscienses Middle East Fzc
Director
Director
EYE-TEC
Director
Director
Metatron Holding
Class B director
Class B director
Oak Projects
Director
Director
Pilot Biologix
Director
Director
Quality for You
Director
Director
Vandermarliere Nicolas
Class B director
Class B director
JTR CONSULTING
Director
Director
BoardEarliermandate already running before its first mention
Mandates as a list
- Chemsciences Middle East Fzc
- Director, appointed by deed of 05-09-2025, still in office
- QbD Growth
- Director, from 16-12-2025 to date
- VANDECRUYS Amber
- Director, from 16-12-2025 to date
- Chemscienses Middle East Fzc
- Director, appointed by deed of 05-01-2026, still in office
- Director, until 05-01-2026
- EYE-TEC
- Director, from 20-08-2019 to 05-01-2026
- Metatron Holding
- Class B director, from 25-09-2023 to 05-01-2026
- Oak Projects
- Director, from 20-08-2019 to 05-01-2026
- Pilot Biologix
- Director, from 20-08-2019 to 05-01-2026
- Quality for You
- Director, from 20-08-2019 to 05-01-2026
- Vandermarliere Nicolas
- Class B director, from 25-09-2023 to 05-01-2026
- JTR CONSULTING
- Director, from 20-08-2019 to 03-02-2022
Control
37.08%
This company
SIMABS
Equity €1.0m
Loss €1.5m in 2025
Capital
- Capital
- €6,221,600
- Shares
- 183,672,625 in the deed of 20-10-2023 and 3 later capital increases
- Contribution per share
- €0.03
- Equity per share
- €0.01 in 2025
- Source
- deed of 13-03-2026
Owners through the years
as the annual accounts name themOwners as a list
- QbD Growth
- Pilot Biologix
- Oak Projects
- Metatron Holding
Source: lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 05-01-2026 (in Dutch)
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 5 directorsAt most 7 directorsTerm of at most 6 yearsdeed of 13-03-2026 (in Dutch)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- 30 June at 14:00deed of 05-01-2026 (in Dutch)
Shareholders
3 ownersOwners 3
- Equity €98.9m Profit of €361,343 in 2025 (loss of €274,471 in 2024)Sourceaccounts QbD Growth 202537.08%
- Equity €398,715 Profit of €20,315 in 2025 (profit of €24,564 in 2024)18.54%
- Equity €414,397 Profit of €89,671 in 2025 (profit of €78,225 in 2024) Checked score 962.91%
Capital transactions
Shareholders according to the deeds
At incorporation
deed of 22-08-2019 ↗
- PILOT BIOLOGIX (BE 0847.681.218) founder
- Oak Projects (BE 0700.965.946) founder
- JTR CONSULTING (BE 0643.786.129) founder
- EYE-TEC (BE 0559.903.992) founder
- QUALITY FOR YOU (BE 0598.934.517) founder
Capital over time
- 13-03-2026 Capital increase of €1,500,000 · to €6,221,600 · 20,280,378 new shares · in cash
- 05-01-2026 Capital increase of €1,335,000 · to €3,241,600 · 18,049,537 new shares at €0.07 per share
- 05-01-2026 Capital increase of €1,500,000 · to €5,771,600 · 20,280,378 new shares
- 20-10-2023 Capital increase of €831,600 · to €1,906,600 · 36,728,999 new shares, 29.4% of the 125,062,332 shares after the increase · in cash
- 03-02-2022 Capital increase of €575,000 · to €1,075,000 · 38,333,333 new shares · in cash
- 03-11-2020 Capital increase of €400,000 · to €500,000 · 40,000,000 new shares · in cash
- 22-08-2019 Incorporation · €100,000 · 10,000,000 shares
Network & group
No group
SIMABS has no parent and no holdings in its annual accounts.
Earlier ties
| QbD Group via Quality for You, at SIMABS until 2026 · Director · deed of 24-10-2022 founded in 2011 · group Quality for You |
179 FTE (2025) |
| Poels via Metatron Holding, at SIMABS until 2026 · Director · deed of 22-10-2024 founded in 1975 |
43 FTE (2025) |
| DADDY KATE via Metatron Holding, at SIMABS until 2026 · Director · deed of 18-06-2021 founded in 2009 · group Nano Capital |
79 FTE (2025) |
| ABN Cleanroom Technology via Metatron Holding, at SIMABS until 2026 · Managing director and chair of the board · deed of 05-01-2024 founded in 2019 |
28 FTE (2025) |
| Aionis via Metatron Holding, at SIMABS until 2026 · Managing director · deed of 03-10-2024 founded in 2024 |
total assets €8.5m (2025) |
| Hamster Cleaning via Metatron Holding, at SIMABS until 2026 · Director · deed of 25-11-2021 founded in 2014 |
25 FTE (2025) |
Show 9 more earlier ties
| TRU via Metatron Holding, at SIMABS until 2026 · Director · deed of 25-10-2019 founded in 2019 |
22 FTE (2025) |
| QbD Wallonia via Quality for You, at SIMABS until 2026 · Director (not named in the articles) · deed of 18-01-2024 founded in 2019 · group Quality for You |
15 FTE (2025) |
| QbD RepS via Quality for You, at SIMABS until 2026 · Director · deed of 06-09-2021 founded in 2000 · group Quality for You |
total assets €1.1m (2025) |
| KENWELD via Metatron Holding, at SIMABS until 2026 · Director · deed of 29-09-2025 founded in 2021 |
total assets €256,849 (2025) |
| QBD CLINICAL HOLDING via QbD Growth (no longer at QBD CLINICAL HOLDING) and Quality for You (at SIMABS until 2026) · deeds of 25-05-2023 and 01-09-2020 No longer active |
total assets €11.3m (2023) |
| Trium Clinical Consulting via QbD Growth (no longer at Trium Clinical Consulting) and Quality for You (at SIMABS until 2026) · deeds of 25-05-2023 and 16-09-2020 No longer active |
64 FTE (2023) |
| Baeten Consultancy & Management via Quality for You, at SIMABS until 2026 · Sole director · deed of 31-08-2022 No longer active |
5.6 FTE (2023) |
| TURNSTONE COMMUNICATIONS via QbD Growth, no longer at TURNSTONE COMMUNICATIONS · Director · deed of 14-06-2023 No longer active · group Quality for You |
total assets €113,661 (2025) |
| HEALTHTOMARKET via Quality for You, at SIMABS until 2026 · Sole director · deed of 28-05-2024 No longer active |
1 FTE (2023) |
Connections & network
2 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
QARAD
via QbD Growth and Quality for You (at SIMABS until 2026) · Director · deeds of 02-09-2026 and 06-09-2021
Founded in 2000 · 4.7 FTE (2025) · group Quality for You
→
Regulatory System Compliance Partners
via QbD Growth · Director · deed of 13-07-2026
Founded in 2012 · 0.3 FTE (2025)
→
Timeline
Timeline
21 events since 2019Board
Capital
Filings
Financial
Permits
Establishments
Other
2020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBfull format · 1 day before the deadline
Capital increase of €1,500,000 to €6,221,600Capital from €4,721,600 to €6,221,600, 20,280,378 new shares · General meeting of 06-03-20263 points ▸
- General meeting, 06-03-2026
- Capital increase, €1,500,000
- Capital, €6,221,600
- The deed holds 1 more point.
Environmental permit granted OmgevingsloketBouwen of herbouwen, Verbouwen en/of uitbreiden zonder functiewijziging en zonder wijziging van aantal woongelegenheden · Provincie Limburg
5 directors appointed, 7 resignationsCapital from €1,906,600 to €3,241,600, 18,049,537 new shares · Capital from €4,271,600 to €5,771,600, 20,280,378 new shares · Contribution of €1,480,000 · General meeting of 16-12-202523 points ▸
- Capital, €4,721,600, 171,878,728 shares
- Director resignation, Pilot Biologix
- Director resignation, EYE-TEC
- Director resignation, Oak Projects
- Director resignation, Metatron Holding
- Director resignation, Chemscienses Middle East Fzc
- Director resignation, Vandermarliere Nicolas
- Director resignation, Quality for You
- Permanent representative, Koen Dierckx
- Permanent representative, Bram Keymolen
- Permanent representative, Joachim Vandeput
- Permanent representative, Jo Nelissen
- Permanent representative, Amit Tibrewala
- Permanent representative, Bart Van Acker, mentioned twice in the deed
- Director appointment, QBD GROWTH
- Director appointment, Pilot Biologix
- Director appointment, Metatron Holding
- Director appointment, Chemscienses Middle East Fzc
- Director appointment, VANDECRUYS Amber
- General meeting, 16-12-2025
- Capital increase, €1,335,000
- Capital contribution, €1,480,000
- Capital increase, €1,500,000
- The deed holds 8 more points.
2025
Weakest financial year net -€1.5m The net result drops to -€1.5m, the lowest from 2020 to 2025.
Registered in the Peppol Directory Reachable for e-invoices through 0208:0732709096
New establishment in Diepenbeek Wetenschapspark 9
1 director appointedChemsciences Middle East Fzc · Permanent representatives: Amit Tibrewala and Koen Dierckx · General meeting of 30-06-20254 points ▸
- General meeting, 30-06-2025
- Director appointment, Chemsciences Middle East Fzc
- Permanent representative, Amit Tibrewala
- Permanent representative, Koen Dierckx
Annual accounts 2024 filed PDFabbreviated format · 8 days before the deadline
2024
Capital increaseGeneral meeting of 14-08-20241 point ▸
- General meeting, 14-08-2024
- The deed holds 8 more points.
Annual accounts 2023 filed PDFmicro format · 2 days before the deadline
2023
Capital increase of €831,600 to €1,906,600Capital from €1,075,000 to €1,906,600, 36,728,999 new shares · Reappointments: Pilot Biologix, EYE-TEC, Oak Projects and Quality for You · Permanent representatives: DIERCKX August Koen, KEYMOLEN Bram, VANDEPUT Joachim, VAN ACKER Bart and NELISSEN Jo · General meeting of 25-09-202319 points ▸
- General meeting, 25-09-2023
- Capital increase, €831,600
- Capital, €1,906,600, 125,062,332 shares
- Director reappointment, Pilot Biologix (class A director)
- Director reappointment, EYE-TEC (class A director)
- Director reappointment, Oak Projects (class A director)
- Director reappointment, Quality for You (class A director)
- Director discharge, Pilot Biologix
- Director discharge, EYE-TEC
- Director discharge, Oak Projects
- Director discharge, Quality for You
- Permanent representative, DIERCKX August Koen
- Permanent representative, KEYMOLEN Bram
- Permanent representative, VANDEPUT Joachim
- Permanent representative, VAN ACKER Bart
- Director appointment, VANDERMARLIERE Nicolas (class B director)
- Director appointment, METATRON HOLDING (class B director)
- Permanent representative, NELISSEN Jo
- Power of attorney, Ann SCHAEKEN
- The deed holds 8 more points.
Annual accounts 2022 filed PDFabbreviated format · 1 day before the deadline
2022
Annual accounts 2021 filed PDFabbreviated format · 28 days before the deadline
Permanent representatives: Bram Keymolen and Koen DierckxBoard meeting of 15-03-20223 points ▸
- Board meeting, 15-03-2022
- Permanent representative, Bram Keymolen
- Permanent representative, Koen Dierckx
Capital increase of €575,000 to €1,075,000Capital from €500,000 to €1,075,000, 38,333,333 new shares · Resignation: JTR CONSULTING (director) · Permanent representative: Johan Trouwers · General meeting of 21-12-20218 points ▸
- General meeting, 21-12-2021
- Capital increase, €575,000
- Capital, €1,075,000
- Amendment of the articles, article 5
- Director resignation, JTR CONSULTING
- Permanent representative, Johan Trouwers
- Director discharge, JTR CONSULTING
- Power of attorney, Ann SCHAEKEN
- The deed holds 1 more point.
2021
Equity above €1m equity €1.0m ▲24.4% Equity rises from €835,361 to €1.0m.
Annual accounts 2020 filed PDFabbreviated format · 23 days before the deadline
2020
Capital increase of €400,000 to €500,000Capital from €100,000 to €500,000, 40,000,000 new shares · General meeting of 22-10-20203 points ▸
- General meeting, 22-10-2020
- Capital increase, €400,000
- Amendment of the articles, article 5
2019
IncorporationFounding capital of €100,000, 10,000,000 shares · Founders: PILOT BIOLOGIX, Oak Projects, JTR CONSULTING and 2 others · Appointments: PILOT BIOLOGIX, Oak Projects, JTR CONSULTING, EYE-TEC and QUALITY FOR YOU · published on 22-08-201918 points ▸
- Founder, PILOT BIOLOGIX
- Founder, Oak Projects
- Founder, JTR CONSULTING
- Founder, EYE-TEC
- Founder, QUALITY FOR YOU
- Founding capital, €100,000, 10,000,000 shares
- Registered office clause, 3590 Diepenbeek, Agoralaan Abis
- Board rule, 5
- Director appointment, PILOT BIOLOGIX
- Permanent representative, August Koen Dierckx
- Director appointment, Oak Projects
- Permanent representative, Joachim Vandeput
- Director appointment, JTR CONSULTING
- Permanent representative, Johan Trouwers
- Director appointment, EYE-TEC
- Permanent representative, Bram Keymolen
- Director appointment, QUALITY FOR YOU
- Permanent representative, Bart Van Acker
- The deed holds 2 more points.
First establishment Agoralaan Abis, Diepenbeek
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
SIMABS was incorporated on 20 August 2019 as a public limited company by PILOT BIOLOGIX, Oak Projects and three other companies, with a starting capital of €100,000.12 Between 2020 and 2026 the capital was increased 5 times, most recently to €6.2m.345 The board currently has 4 members.6 Total assets rose from €1.4m in 2020 to €2.7m in 2025 and headcount from 1.3 to 11.4 full-time equivalents.7
Company details
Identity
- Enterprise number
- 0732.709.096
- VAT number
- BE 0732.709.096
- Peppol ID
- 0208:0732709096
- Other Peppol ID
- 9925:BE0732709096
- Legal form
- Public limited company
- Status
- Active, normal situation
- Founded
- 20-08-2019
- Financial year
- ends on 31 December
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- 30 June at 14:00deed of 05-01-2026 (in Dutch)
- Website
- www.simabs.com
- Peppol
- Reachable since 25-11-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- SIMABS in Dutch
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 05-01-2026 (in Dutch)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”deed of 05-01-2026 (in Dutch)
Activities
NACEBEL 2025VAT activities
21201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
Social security (RSZ) activities
72101
Research and development on biotechnology main activity
Joint committees annual accounts 2025
JC 207
White-collar workers in the chemical industry
Codes under NACEBEL 2008
VAT activities
21201
Manufacture of basic pharmaceutical products and pharmaceutical preparations main activity
21100
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209
Manufacture of basic pharmaceutical products and pharmaceutical preparations
Social security (RSZ) activities
72110
Scientific research and development main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Ontwikkeling, productie, diensten en verkoop van biotechnologische geneesmiddelen. Het verlenen van diensten kan zich uiten onder de vorm…”deed of 05-01-2026 (in Dutch)
20 activities
- Ontwikkeling, productie, diensten en verkoop van biotechnologische geneesmiddelen. Het verlenen van diensten kan zich uiten onder de vorm van project management, technologie transfer, onderzoek en ontwikkeling, operationeel management, algemeen management en people management
- Wetenschappelijke, technische en commerciële adviesverlening en onderricht op gebied van ontwikkeling, productie en verkoop van geneesmiddelen en biotechnologie
- Het geven van trainingen in verband met ontwikkeling, productie en verkoop van geneesmiddelen en biotechnologie
- Het verlenen en vragen van managementdiensten onder welke vorm ook, consultancy aan vennootschappen, verenigingen en ondernemingen in het algemeen
- Het beheer van patrimonium
- Het nemen van participaties in andere ondernemingen
- Het verwerven, beheren en verkopen van onroerende goederen of zakelijke rechten daarop, in België of in het buitenland
- Het huren, verhuren, in erfpacht of gebruik nemen van onroerend en/of roerend patrimonium bestaande uit lichamelijke of onlichamelijke onroerende en/of roerende goederen
- Het aangaan van leningen en financiering
- Functies van bestuurder of vereffenaar in andere vennootschappen uitoefenen
- Het leveren van diensten van projectmanagement, waaronder het uitvoeren van haalbaarheidsstudies, het opstellen en laten opstellen van ontwerpen, plannen en beschrijvingen die in bestekken moeten worden ingelast
- Het voorbereiden van documenten voor offerteaanvragen, met inbegrip van contractvoorwaarden
- Het geven van adviezen op technisch vlak
- Het beheer van uitvoering van werken
- Het waarmerken van betalingsaanvragen
- Het vaststellen van gebreken
- Het nemen van maatregelen indien zich omstandigheden voordoen die de stipte uitvoering van de werken in gedrang brengen
- Het uitvoeren van inspecties en keuringen
- Het verlenen van bijstand bij voorlopige en definitieve opleveringen
- Opstart, commissioning, kwalificatie en validatie van gebouwen, nutsvoorzieningen, industriële machines, processen en systemen
Registered office and establishments
2 establishments| Establishment | Since | Unit number |
|---|---|---|
| Agoralaan Abis registered office 3590 Diepenbeek | 20-08-2019 | 2.292.355.864 |
| Wetenschapspark 9 3590 Diepenbeek | 25-09-2025 | 2.378.436.337 |
Buildings and parcels at the addresses
- Ground area
- 2,465 m²
- Buildings
- 595 m²
- Volume, LiDAR
- 3,890 m³
- Tallest building
- 7.4 m
Buildings to scale, each on its own parcel
Environmental permits
1 application in Flanders since 2025 · 1 granted| 25-02-2026 | Granted | Bouwen of herbouwen; Verbouwen en/of uitbreiden zonder functiewijziging en zonder wijziging van aantal woongelegenheden submitted 22-07-2025 · project 2025049265 | Provincie Limburg |
Source: Omgevingsloket Vlaanderen.
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 71011A0098/00L000 | 2,465 m² | 1 · 595 m² | 7.4 m · 2 |
Contact
E-mail
info@simabs.com